Phase 2b-ready program targeting neuroinflammation in mild Alzheimer's disease complements lead program Ismidenon in moderate Alzheimer's
AMSTERDAM, Nov. 16, 2026 /PRNewswire/ -- AmyriAD Therapeutics B.V. ("AmyriAD"), a clinical-stage biopharmaceutical company developing therapies that address biological drivers of cognitive decline, today announced the acquisition of the AD04 Alzheimer's disease program and related assets from ADvantage Therapeutics, Inc. ("ADvantage"). The acquisition adds a Phase 2b-ready program targeting neuroinflammation in mild Alzheimer's disease, complementing AmyriAD's lead program, Ismidenon, in moderate Alzheimer's.
AD04 is an investigational drug subcutaneously administered. Its mechanism of action is initiated by peripheral inflammation and results in inflammation resolution in the brain and the elimination of waste, including lipid microdroplets.
Strategic Rationale
"Cognitive decline threatens people's independence, relationships and daily lives. Addressing it requires more treatment options across different biological mechanisms and stages of disease," said K. Ranga Rama Krishnan, Chairman of the Board and CEO of AmyriAD. "Following our acquisition of Recognify Life Sciences, AD04 further expands our cognition pipeline alongside lead program Ismidenon. We are building this portfolio with a clear purpose: helping people preserve the abilities that make life their own."
"AD04's clinical findings provide a compelling foundation for its continued development in mild Alzheimer's disease," said Jeffrey B. Madden, Chief Executive Officer of ADvantage Therapeutics. "I'm excited to combine our experience with AD04 and AmyriAD's expertise in cognition as we advance toward Phase 2b, building on the program's Innovation Passport under the United Kingdom's Innovative Licensing and Access Pathway (ILAP)."
AD04's clinical rationale emerged from AFF006, a 332-patient Phase 2 Alzheimer's vaccine study. In this study, AD04 served as a control treatment. AD04 is based on a proprietary formulation of aluminum hydroxide hydrogel with a specific dosage. Exploratory post hoc analyses of patients who received AD04 identified signals of slower cognitive decline and reduced hippocampal volume loss.
Development Plan
AmyriAD intends to advance AD04 into Phase 2b development in mild Alzheimer's disease to prospectively evaluate its safety and efficacy. The program has received an Innovation Passport under the United Kingdom's Innovative Licensing and Access Pathway.
Transaction Details
Under the terms of the agreement, AmyriAD acquired worldwide rights to AD04, including associated intellectual property, clinical data and regulatory assets.
Jeffrey B. Madden and members of ADvantage's clinical and scientific team will continue to support AD04 in advisory roles, providing continuity and program expertise as AmyriAD advances development.
About AD04
AD04 is an investigational drug, subcutaneously administered, based on an aluminum hydroxide hydrogel, with a specific and proprietary dosage. Its proposed mechanism targets immune processes relevant to neuroinflammation.
About Ismidenon (AD-101)
Ismidenon (AD-101) is AmyriAD's lead investigational program, being developed as an oral add-on symptomatic treatment for cognitive impairment in moderate Alzheimer's disease. It targets presynaptic T-type calcium channels to increase acetylcholine release. Studied in more than 500 patients, Ismidenon is moving to a Phase 2 study.
About RL-007 (Inidascamine)
RL-007 is an investigational oral small molecule being developed for cognitive impairment. It modulates cholinergic, glutamatergic and gamma-aminobutyric acid type B (GABA-B) receptor signaling and has completed Phase 2a and Phase 2b studies in cognitive impairment associated with schizophrenia. AmyriAD plans extended-release formulation development and a pharmacokinetic study to guide further development.
About AmyriAD Therapeutics
AmyriAD Therapeutics B.V. is a clinical-stage biopharmaceutical company developing therapies targeting biological drivers of cognitive decline. Anchored by lead program Ismidenon (AD-101), AmyriAD is building a portfolio of complementary programs across biological mechanisms and stages of cognitive decline, each with its own clinical development path. AmyriAD is headquartered in Amsterdam, the Netherlands. Visit www.amyriadtherapeutics.com.
Forward-Looking Statements
This release contains forward-looking statements regarding the acquisition's anticipated benefits and planned clinical development. Actual results may differ materially due to clinical, regulatory, financing and other drug-development risks. Earlier findings may not be replicated. AmyriAD undertakes no obligation to update these statements except as required by law.
Contacts
Kim Bruin, [email protected] (Investors)
Ankil Patel, 917-561-6464, [email protected] (Media)
SOURCE AmyriAD Therapeutics

Share this article